Patents by Inventor Ramkumar Modukuri

Ramkumar Modukuri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME
    Publication number: 20250304550
    Abstract: The present disclosure relates to compounds which inhibit bromodomain testis (BRDT). In certain embodiments, the compound is a bromodomain and extra-terminal (BET) subfamily bromodomain 1 (BD1) selective compound. In certain embodiments, the compound selectively inhibits BD-1 over bromodomain 2 (BD2). The present disclosure further provides a method of inhibiting BRDT in a male subject, the method comprising administering to the male subject a therapeutically effective amount of a compound of the disclosure, whereby the male subject is provided a contraceptive effect.
    Type: Application
    Filed: April 6, 2023
    Publication date: October 2, 2025
    Inventors: Martin Matzuk, Zhifeng Yu, Ramkumar Modukuri, Feng Li, Damian Young, Melek Nihan Ucisik, John Faver, Zhi Tan, Zhuang Jin, Justin Anglin, Mingxing Teng, Choel Kim
  • Agonists of stimulator of interferon genes sting
    Patent number: 11701364
    Abstract: The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (I): as defined herein. Compounds for practice of a method of the invention can be delivered via oral delivery for systemic exposure, as well as delivered intratumorally. Antitumor therapy using a compound of formula (I) can further comprise administration of an effective dose of an immune-checkpoint targeting drug.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: July 18, 2023
    Assignee: The Scripps Research Institute
    Inventors: Luke L. Lairson, Emily Chin, Arnab K. Chatterjee, Manoj Kumar, Ana Maria Gamo Albero, Hank Michael James Petrassi, Peter G. Schultz, Chenguang Yu, Junko Tamiya, William Vernier, Anil Gupta, Ramkumar Modukuri
  • AGONISTS OF STIMULATOR OF INTERFERON GENES STING
    Publication number: 20210205321
    Abstract: The invention provides compounds having STimulator of INterferon Genes (STING) agonistic bioactivity that can be used in the treatment of tumors in patients afflicted therewith. The compounds are of formula (I): as defined herein. Compounds for practice of a method of the invention can be delivered via oral delivery for systemic exposure, as well as delivered intratumorally. Antitumor therapy using a compound of formula (I) can further comprise administration of an effective dose of an immune-checkpoint targeting drug.
    Type: Application
    Filed: February 21, 2019
    Publication date: July 8, 2021
    Inventors: Luke L. Lairson, Emily Chin, Arnab K. Chatterjee, Manoj Kumar, Ana Maria Gamo Albero, Hank Michael James Petrassi, Peter G. Schultz, Chenguang Yu, Junko Tamiya, William Vernier, Anil Gupta, Ramkumar Modukuri